Antiplatelet Therapy during the First Year after Acute Coronary Syndrome in a Contemporary Italian Community of over 5 Million Subjects

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/1000000154
• EU PAS number:
  EUPAS1000000154
• Study ID:
  1000000154
• Official title and acronym:
  Antiplatelet Therapy during the First Year after Acute Coronary Syndrome in a Contemporary Italian Community of over 5 Million Subjects
• DARWIN EU® study:
  No
• Study countries:
  Italy
• Study description:
  An observational retrospective non-interventional cohort study that has described patterns of antiplatelet therapy (APT) during the year following a hospital diagnosis of acute coronary syndrome (ACS) and possible implications in terms of revascularization rates, rehospitalizations, and costs for the Italian National Health Service (SSN).
• Study status:
  Finalised

Research institution and networks

Institutions

Fondazione ReS (Ricerca e Salute), CINECA partner

Italy

Contact details

Silvia Calabria

Study contact

[e-mail]

Letizia Dondi

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 08/01/2021

Data collection

Actual: 08/02/2021

Date of final study report

Actual: 08/06/2021

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

This research was partially funded by Sanofi Italy. No grant number has been generated. The funders had no role in the design of the study; in the collection, analyses, or interpretation of the data; in the writing of the manuscript, or in the decision to publish the results.

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable